Regadenoson
Cat. No.：YN1441176
CAS No. ：313348-27-5
| 产品名称: | Regadenoson |
| CAS No.: | 313348-27-5 |
| Chemical Name: | 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-adenosine |
| Synonyms: | 瑞加德松; CVT-3146 |
| 分子量: | 390.35 |
| 分子式: | C₁₅H₁₈N₈O₅ |
| SMILES: | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=C(N4N=CC(C(NC)=O)=C4)N=C3N)O1)O)O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Regadenoson (CVT-3146) 是一种有效的选择性A2A腺苷受体激动剂，对大鼠和猪腺苷 A2A 受体的Ki分别为 290 和 1120 nM。Regadenoson 对 A2A 受体的选择性高于人 A1 和 A2B 受体，其选择性是 A1 受体的 13 倍。Regadenoson 是一种血管扩张剂，它改变了血管扩张剂心肌灌注显像的前景。Regadenoson 增加了啮齿动物血脑屏障 (BBB) 的通透性。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Gao, Z., Li, Z., Baker, S.P., et al.Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonistsJ. Pharmacol. Exp. Ther.298(1),209-218(2001)
Zhao, G., Linke, A., Xu, X., et al.Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogsJ. Pharmacol. Exp. Ther.307(1),182-189(2003)
Bhatti, S., Hakeem, A., Dhanalakota, S., et al.Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunctionEur.Heart J.Cardiovasc.Imaging15(8),933-940(2014)
Verberne, H.J., Acampa, W., Anagnostopoulos, C., et al.EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revisionEur. J. Nucl. Med. Mol. Imaging42(12),1929-1940(2015)
Carman, A.J., Mills, J.H., Krenz, A., et al.Adenosine receptor signaling modulates permeability of the blood-brain barrierJ. Neurosci.31(37),13272-13280(2011)
Jackson, S., Anders, N.M., Mangraviti, A., et al.The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brainJ. Neurooncol.126(3),433-439(2016)
